Remote Monitoring Boosts Decentralized Trials
An influx in technologies is making it easier for pharma companies to conduct decentralized trials for all therapeutic areas, but designers of these trials need confidence in the technology’s effectiveness.
That’s why, as a RPM manufacturer, AliveCor prioritizes proving the effectiveness. For example, AliveCor received FDA clearance in 2021 for healthcare professionals to use KardiaMobile 6L to collect a crucial piece of information about patients’ heart health: their QTc interval.
For many trials, proven RPM technology showcases that the opportunity to decentralize has arrived.
Key Takeaways:
- The more companies embrace RPM tools, the faster we’ll normalize decentralized trials
- Decentralized trials benefit the patient and sponsor
- The RPM industry is growing rapidly
- Demonstrating results and undergoing pilot programs is important to RPM manufacturers like AliveCor
In The News
12 Ways to Improve Adherence
PM360online.com | With treatment plans that require frequent ECG testing, patients with breast cancer are faced with even more challenges. Leveraging KardiaMobile® 6L, an IQVIA program alleviated the pains associated with traditional 12-lead systems.
At-Home Clinical Trials Are the Future
StatNews.com | Hybrid and decentralized clinical trials are rapidly advancing. To ensure DCT success, mobile digital health technologies, like portable ECGs, are proving more necessary than ever.
Remote Monitoring Boosts Decentralized Trials
PharmExec.com | Decentralized trials are known to have positive effects, but sponsors have concerns about how to monitor patients well. Remote patient monitoring (RPM) solutions, like those from AliveCor, are changing this paradigm. The benefits that decentralized trials offer patients and sponsors are evident. Yet, decentralized trials are still lacking.